Suzuki S, Moore D H, Ginzinger D G, Godfrey T E, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray J W
Cancer Center, University of California, San Francisco, 94143-0808, USA.
Cancer Res. 2000 Oct 1;60(19):5382-5.
This report describes analyses of associations of genome copy number abnormalities in ovarian cancers with clinical features using genome-wide graphical and analytical procedures. These studies show that tumor grade is a better indicator of the extent of genomic progression than stage, that loss of chromosome 4 occurs preferentially in high-grade tumors, and that gains of 3q26-qter, 8q24-qter, and 20q13-qter occur frequently in low-grade and low-stage tumors and thus may be early events in ovarian cancer development. In addition, loss of chromosome 16q24 and a total number of independent genome copy number aberrations >7 are associated with reduced survival duration. The association of loss of 16q24 (D16S3026) with decreased survival duration was confirmed by quantitative PCR. Regions that frequently are abnormal and associated with altered survival duration are strong candidates for higher resolution analysis and gene discovery and may be useful markers for prediction of clinical outcome.
本报告描述了使用全基因组图形和分析程序对卵巢癌基因组拷贝数异常与临床特征之间的关联进行的分析。这些研究表明，肿瘤分级比分期更能准确反映基因组进展程度；4号染色体缺失优先发生于高级别肿瘤；3q26-qter、8q24-qter和20q13-qter的扩增在低级别和低分期肿瘤中频繁出现，因此可能是卵巢癌发生的早期事件。此外，16q24染色体缺失以及独立基因组拷贝数畸变总数>7与生存期缩短相关。通过定量PCR证实了16q24（D16S3026）缺失与生存期缩短之间的关联。频繁出现异常且与生存期改变相关的区域是进行高分辨率分析和基因发现的有力候选对象，可能是预测临床结局的有用标志物。
